1
|
Dubois-Deruy E, El Masri Y, Turkieh A, Amouyel P, Pinet F, Annicotte JS. Cardiac Acetylation in Metabolic Diseases. Biomedicines 2022; 10:biomedicines10081834. [PMID: 36009379 PMCID: PMC9405459 DOI: 10.3390/biomedicines10081834] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2022] [Revised: 07/27/2022] [Accepted: 07/28/2022] [Indexed: 11/17/2022] Open
Abstract
Lysine acetylation is a highly conserved mechanism that affects several biological processes such as cell growth, metabolism, enzymatic activity, subcellular localization of proteins, gene transcription or chromatin structure. This post-translational modification, mainly regulated by lysine acetyltransferase (KAT) and lysine deacetylase (KDAC) enzymes, can occur on histone or non-histone proteins. Several studies have demonstrated that dysregulated acetylation is involved in cardiac dysfunction, associated with metabolic disorder or heart failure. Since the prevalence of obesity, type 2 diabetes or heart failure rises and represents a major cause of cardiovascular morbidity and mortality worldwide, cardiac acetylation may constitute a crucial pathway that could contribute to disease development. In this review, we summarize the mechanisms involved in the regulation of cardiac acetylation and its roles in physiological conditions. In addition, we highlight the effects of cardiac acetylation in physiopathology, with a focus on obesity, type 2 diabetes and heart failure. This review sheds light on the major role of acetylation in cardiovascular diseases and emphasizes KATs and KDACs as potential therapeutic targets for heart failure.
Collapse
|
2
|
El Masri Y, Pichavant M, Chwastyniak M, Kervoaze G, Besème O, Grangette C, Gosset P, Wolowczuk I, Pinet F, Turkieh A, Dubois-Deruy E. Role of oxidative stress in cardiac remodeling induced by the HFD diet and cigarette smoke exposure. Archives of Cardiovascular Diseases Supplements 2022. [DOI: 10.1016/j.acvdsp.2022.04.078] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
3
|
Peugnet V, Chwastyniak M, Mulder P, Lancel S, Bultot L, Fourny N, Renguet E, Bugger H, Beseme O, Loyens A, Heyse W, Richard V, Amouyel P, Bertrand L, Pinet F, Dubois-Deruy E. Mitochondrial-Targeted Therapies Require Mitophagy to Prevent Oxidative Stress Induced by SOD2 Inactivation in Hypertrophied Cardiomyocytes. Antioxidants (Basel) 2022; 11:antiox11040723. [PMID: 35453408 PMCID: PMC9029275 DOI: 10.3390/antiox11040723] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2022] [Revised: 03/30/2022] [Accepted: 04/04/2022] [Indexed: 12/24/2022] Open
Abstract
Heart failure, mostly associated with cardiac hypertrophy, is a major cause of illness and death. Oxidative stress causes accumulation of reactive oxygen species (ROS), leading to mitochondrial dysfunction, suggesting that mitochondria-targeted therapies could be effective in this context. The purpose of this work was to determine whether mitochondria-targeted therapies could improve cardiac hypertrophy induced by mitochondrial ROS. We used neonatal (NCMs) and adult (ACMs) rat cardiomyocytes hypertrophied by isoproterenol (Iso) to induce mitochondrial ROS. A decreased interaction between sirtuin 3 and superoxide dismutase 2 (SOD2) induced SOD2 acetylation on lysine 68 and inactivation, leading to mitochondrial oxidative stress and dysfunction and hypertrophy after 24 h of Iso treatment. To counteract these mechanisms, we evaluated the impact of the mitochondria-targeted antioxidant mitoquinone (MitoQ). MitoQ decreased mitochondrial ROS and hypertrophy in Iso-treated NCMs and ACMs but altered mitochondrial structure and function by decreasing mitochondrial respiration and mitophagy. The same decrease in mitophagy was found in human cardiomyocytes but not in fibroblasts, suggesting a cardiomyocyte-specific deleterious effect of MitoQ. Our data showed the importance of mitochondrial oxidative stress in the development of cardiomyocyte hypertrophy. We observed that targeting mitochondria by MitoQ in cardiomyocytes impaired the metabolism through defective mitophagy, leading to accumulation of deficient mitochondria.
Collapse
Affiliation(s)
- Victoriane Peugnet
- Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1167-RID-AGE-Facteurs de Risque et Déterminants Moléculaires des Maladies Liées au Vieillissement, 59000 Lille, France; (V.P.); (M.C.); (S.L.); (O.B.); (W.H.); (P.A.)
| | - Maggy Chwastyniak
- Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1167-RID-AGE-Facteurs de Risque et Déterminants Moléculaires des Maladies Liées au Vieillissement, 59000 Lille, France; (V.P.); (M.C.); (S.L.); (O.B.); (W.H.); (P.A.)
| | - Paul Mulder
- Normandie Univ, UNIROUEN, Inserm U1096, FHU-REMOD-HF, 76000 Rouen, France; (P.M.); (V.R.)
| | - Steve Lancel
- Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1167-RID-AGE-Facteurs de Risque et Déterminants Moléculaires des Maladies Liées au Vieillissement, 59000 Lille, France; (V.P.); (M.C.); (S.L.); (O.B.); (W.H.); (P.A.)
| | - Laurent Bultot
- Pole of Cardiovascular Research, Institut de Recherche Expérimentale et Clinique, UCLouvain, 1200 Bruxelles, Belgium; (L.B.); (N.F.); (E.R.); (L.B.)
| | - Natacha Fourny
- Pole of Cardiovascular Research, Institut de Recherche Expérimentale et Clinique, UCLouvain, 1200 Bruxelles, Belgium; (L.B.); (N.F.); (E.R.); (L.B.)
| | - Edith Renguet
- Pole of Cardiovascular Research, Institut de Recherche Expérimentale et Clinique, UCLouvain, 1200 Bruxelles, Belgium; (L.B.); (N.F.); (E.R.); (L.B.)
| | - Heiko Bugger
- Department of Cardiology and Angiology I, Heart Center Freiburg, Faculty of Medicine, University of Freiburg, 79085 Freiburg, Germany;
| | - Olivia Beseme
- Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1167-RID-AGE-Facteurs de Risque et Déterminants Moléculaires des Maladies Liées au Vieillissement, 59000 Lille, France; (V.P.); (M.C.); (S.L.); (O.B.); (W.H.); (P.A.)
| | - Anne Loyens
- Univ. Lille, CNRS, Inserm, CHU Lille, Institut de Recherche Contre le Cancer de Lille, UMR9020-UMR-S 1277-Canther-Cancer Heterogeneity, Plasticity and Resistance to Therapies, 59000 Lille, France;
| | - Wilfried Heyse
- Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1167-RID-AGE-Facteurs de Risque et Déterminants Moléculaires des Maladies Liées au Vieillissement, 59000 Lille, France; (V.P.); (M.C.); (S.L.); (O.B.); (W.H.); (P.A.)
| | - Vincent Richard
- Normandie Univ, UNIROUEN, Inserm U1096, FHU-REMOD-HF, 76000 Rouen, France; (P.M.); (V.R.)
| | - Philippe Amouyel
- Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1167-RID-AGE-Facteurs de Risque et Déterminants Moléculaires des Maladies Liées au Vieillissement, 59000 Lille, France; (V.P.); (M.C.); (S.L.); (O.B.); (W.H.); (P.A.)
| | - Luc Bertrand
- Pole of Cardiovascular Research, Institut de Recherche Expérimentale et Clinique, UCLouvain, 1200 Bruxelles, Belgium; (L.B.); (N.F.); (E.R.); (L.B.)
| | - Florence Pinet
- Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1167-RID-AGE-Facteurs de Risque et Déterminants Moléculaires des Maladies Liées au Vieillissement, 59000 Lille, France; (V.P.); (M.C.); (S.L.); (O.B.); (W.H.); (P.A.)
- Correspondence: (F.P.); (E.D.-D.); Tel.: +33-(0)3-20-87-72-15 (F.P.); +33-(0)3-20-87-73-62 (E.D.-D.)
| | - Emilie Dubois-Deruy
- Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1167-RID-AGE-Facteurs de Risque et Déterminants Moléculaires des Maladies Liées au Vieillissement, 59000 Lille, France; (V.P.); (M.C.); (S.L.); (O.B.); (W.H.); (P.A.)
- Correspondence: (F.P.); (E.D.-D.); Tel.: +33-(0)3-20-87-72-15 (F.P.); +33-(0)3-20-87-73-62 (E.D.-D.)
| |
Collapse
|
4
|
Turkieh A, El Masri Y, Pinet F, Dubois-Deruy E. Mitophagy Regulation Following Myocardial Infarction. Cells 2022; 11:cells11020199. [PMID: 35053316 PMCID: PMC8774240 DOI: 10.3390/cells11020199] [Citation(s) in RCA: 17] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2021] [Revised: 12/27/2021] [Accepted: 01/04/2022] [Indexed: 02/07/2023] Open
Abstract
Mitophagy, which mediates the selective elimination of dysfunctional mitochondria, is essential for cardiac homeostasis. Mitophagy is regulated mainly by PTEN-induced putative kinase protein-1 (PINK1)/parkin pathway but also by FUN14 domain-containing 1 (FUNDC1) or Bcl2 interacting protein 3 (BNIP3) and BNIP3-like (BNIP3L/NIX) pathways. Several studies have shown that dysregulated mitophagy is involved in cardiac dysfunction induced by aging, aortic stenosis, myocardial infarction or diabetes. The cardioprotective role of mitophagy is well described, whereas excessive mitophagy could contribute to cell death and cardiac dysfunction. In this review, we summarize the mechanisms involved in the regulation of cardiac mitophagy and its role in physiological condition. We focused on cardiac mitophagy during and following myocardial infarction by highlighting the role and the regulation of PI NK1/parkin-; FUNDC1-; BNIP3- and BNIP3L/NIX-induced mitophagy during ischemia and reperfusion.
Collapse
|
5
|
El Idrissi F, Fruchart M, Belarbi K, Lamer A, Dubois-Deruy E, Lemdani M, N’Guessan AL, Guinhouya BC, Zitouni D. Exploration of the core protein network under endometriosis symptomatology using a computational approach. Front Endocrinol (Lausanne) 2022; 13:869053. [PMID: 36120440 PMCID: PMC9478376 DOI: 10.3389/fendo.2022.869053] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/09/2022] [Accepted: 08/17/2022] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND Endometriosis is defined by implantation and invasive growth of endometrial tissue in extra-uterine locations causing heterogeneous symptoms, and a unique clinical picture for each patient. Understanding the complex biological mechanisms underlying these symptoms and the protein networks involved may be useful for early diagnosis and identification of pharmacological targets. METHODS In the present study, we combined three approaches (i) a text-mining analysis to perform a systematic search of proteins over existing literature, (ii) a functional enrichment analysis to identify the biological pathways in which proteins are most involved, and (iii) a protein-protein interaction (PPI) network to identify which proteins modulate the most strongly the symptomatology of endometriosis. RESULTS Two hundred seventy-eight proteins associated with endometriosis symptomatology in the scientific literature were extracted. Thirty-five proteins were selected according to degree and betweenness scores criteria. The most enriched biological pathways associated with these symptoms were (i) Interleukin-4 and Interleukin-13 signaling (p = 1.11 x 10-16), (ii) Signaling by Interleukins (p = 1.11 x 10-16), (iii) Cytokine signaling in Immune system (p = 1.11 x 10-16), and (iv) Interleukin-10 signaling (p = 5.66 x 10-15). CONCLUSION Our study identified some key proteins with the ability to modulate endometriosis symptomatology. Our findings indicate that both pro- and anti-inflammatory biological pathways may play important roles in the symptomatology of endometriosis. This approach represents a genuine systemic method that may complement traditional experimental studies. The current data can be used to identify promising biomarkers for early diagnosis and potential therapeutic targets.
Collapse
Affiliation(s)
- Fatima El Idrissi
- Univ. Lille, UFR 3S, Faculté Ingénierie et Management de la Santé, Lille, France
- Univ. Lille, UFR 3S, Faculté de Pharmacie, Lille, France
| | - Mathilde Fruchart
- Univ. Lille, UFR 3S, Faculté Ingénierie et Management de la Santé, Lille, France
- Univ. Lille, CHU Lille, ULR 2694 - METRICS, Lille, France
| | - Karim Belarbi
- Univ. Lille, UFR 3S, Faculté de Pharmacie, Lille, France
- Univ. Lille, Inserm, CHU-Lille, Lille Neuroscience & Cognition, Lille, France
| | - Antoine Lamer
- Univ. Lille, UFR 3S, Faculté Ingénierie et Management de la Santé, Lille, France
- Univ. Lille, CHU Lille, ULR 2694 - METRICS, Lille, France
| | - Emilie Dubois-Deruy
- Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1167 - RID-AGE - Facteurs de risque et déterminants moléculaires des maladies liées au vieillissement, Lille, France
| | - Mohamed Lemdani
- Univ. Lille, UFR 3S, Faculté de Pharmacie, Lille, France
- Univ. Lille, CHU Lille, ULR 2694 - METRICS, Lille, France
| | - Assi L. N’Guessan
- Univ. Lille, UMR CNRS 8524, Laboratoire Paul Painlevé, Villeneuve d’Ascq, Cedex, France
| | - Benjamin C. Guinhouya
- Univ. Lille, UFR 3S, Faculté Ingénierie et Management de la Santé, Lille, France
- Univ. Lille, CHU Lille, ULR 2694 - METRICS, Lille, France
- *Correspondence: Benjamin C. Guinhouya,
| | - Djamel Zitouni
- Univ. Lille, UFR 3S, Faculté de Pharmacie, Lille, France
- Univ. Lille, CHU Lille, ULR 2694 - METRICS, Lille, France
| |
Collapse
|
6
|
Rémy G, Dubois-Deruy E, Alard J, Kervoaze G, Chwastyniak M, Baron M, Beury D, Siegwald L, Caboche S, Hot D, Gosset P, Grangette C, Pinet F, Wolowczuk I, Pichavant M. Erratum: Rémy et al. Modelling the Impact of Chronic Cigarette Smoke Exposure in Obese Mice: Metabolic, Pulmonary, Intestinal, and Cardiac Issues. Nutrients 2020, 12, 827. Nutrients 2021; 13:nu13093084. [PMID: 34579176 PMCID: PMC8465400 DOI: 10.3390/nu13093084] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2021] [Accepted: 07/27/2021] [Indexed: 11/16/2022] Open
Abstract
The authors have requested that the following changes be made to their paper [...].
Collapse
Affiliation(s)
- Gaëlle Rémy
- CIIL-Center for Infection and Immunity of Lille, Institut Pasteur de Lille, University of Lille, CNRS UMR9017, Inserm U1019, CHRU Lille, F-59000 Lille, France; (G.R.); (J.A.); (G.K.); (M.B.); (D.B.); (L.S.); (S.C.); (D.H.); (P.G.); (C.G.); (I.W.)
| | - Emilie Dubois-Deruy
- Inserm, CHU Lille, Institut Pasteur de Lille, University of Lille, U1167-RID-AGE-Facteurs de Risque et Déterminants Moléculaires des Maladies liées au Vieillissement, F-59000 Lille, France; (E.D.-D.); (M.C.); (F.P.)
| | - Jeanne Alard
- CIIL-Center for Infection and Immunity of Lille, Institut Pasteur de Lille, University of Lille, CNRS UMR9017, Inserm U1019, CHRU Lille, F-59000 Lille, France; (G.R.); (J.A.); (G.K.); (M.B.); (D.B.); (L.S.); (S.C.); (D.H.); (P.G.); (C.G.); (I.W.)
| | - Gwenola Kervoaze
- CIIL-Center for Infection and Immunity of Lille, Institut Pasteur de Lille, University of Lille, CNRS UMR9017, Inserm U1019, CHRU Lille, F-59000 Lille, France; (G.R.); (J.A.); (G.K.); (M.B.); (D.B.); (L.S.); (S.C.); (D.H.); (P.G.); (C.G.); (I.W.)
| | - Maggy Chwastyniak
- Inserm, CHU Lille, Institut Pasteur de Lille, University of Lille, U1167-RID-AGE-Facteurs de Risque et Déterminants Moléculaires des Maladies liées au Vieillissement, F-59000 Lille, France; (E.D.-D.); (M.C.); (F.P.)
| | - Morgane Baron
- CIIL-Center for Infection and Immunity of Lille, Institut Pasteur de Lille, University of Lille, CNRS UMR9017, Inserm U1019, CHRU Lille, F-59000 Lille, France; (G.R.); (J.A.); (G.K.); (M.B.); (D.B.); (L.S.); (S.C.); (D.H.); (P.G.); (C.G.); (I.W.)
| | - Delphine Beury
- CIIL-Center for Infection and Immunity of Lille, Institut Pasteur de Lille, University of Lille, CNRS UMR9017, Inserm U1019, CHRU Lille, F-59000 Lille, France; (G.R.); (J.A.); (G.K.); (M.B.); (D.B.); (L.S.); (S.C.); (D.H.); (P.G.); (C.G.); (I.W.)
| | - Léa Siegwald
- CIIL-Center for Infection and Immunity of Lille, Institut Pasteur de Lille, University of Lille, CNRS UMR9017, Inserm U1019, CHRU Lille, F-59000 Lille, France; (G.R.); (J.A.); (G.K.); (M.B.); (D.B.); (L.S.); (S.C.); (D.H.); (P.G.); (C.G.); (I.W.)
| | - Ségolène Caboche
- CIIL-Center for Infection and Immunity of Lille, Institut Pasteur de Lille, University of Lille, CNRS UMR9017, Inserm U1019, CHRU Lille, F-59000 Lille, France; (G.R.); (J.A.); (G.K.); (M.B.); (D.B.); (L.S.); (S.C.); (D.H.); (P.G.); (C.G.); (I.W.)
| | - David Hot
- CIIL-Center for Infection and Immunity of Lille, Institut Pasteur de Lille, University of Lille, CNRS UMR9017, Inserm U1019, CHRU Lille, F-59000 Lille, France; (G.R.); (J.A.); (G.K.); (M.B.); (D.B.); (L.S.); (S.C.); (D.H.); (P.G.); (C.G.); (I.W.)
| | - Philippe Gosset
- CIIL-Center for Infection and Immunity of Lille, Institut Pasteur de Lille, University of Lille, CNRS UMR9017, Inserm U1019, CHRU Lille, F-59000 Lille, France; (G.R.); (J.A.); (G.K.); (M.B.); (D.B.); (L.S.); (S.C.); (D.H.); (P.G.); (C.G.); (I.W.)
| | - Corinne Grangette
- CIIL-Center for Infection and Immunity of Lille, Institut Pasteur de Lille, University of Lille, CNRS UMR9017, Inserm U1019, CHRU Lille, F-59000 Lille, France; (G.R.); (J.A.); (G.K.); (M.B.); (D.B.); (L.S.); (S.C.); (D.H.); (P.G.); (C.G.); (I.W.)
| | - Florence Pinet
- Inserm, CHU Lille, Institut Pasteur de Lille, University of Lille, U1167-RID-AGE-Facteurs de Risque et Déterminants Moléculaires des Maladies liées au Vieillissement, F-59000 Lille, France; (E.D.-D.); (M.C.); (F.P.)
| | - Isabelle Wolowczuk
- CIIL-Center for Infection and Immunity of Lille, Institut Pasteur de Lille, University of Lille, CNRS UMR9017, Inserm U1019, CHRU Lille, F-59000 Lille, France; (G.R.); (J.A.); (G.K.); (M.B.); (D.B.); (L.S.); (S.C.); (D.H.); (P.G.); (C.G.); (I.W.)
| | - Muriel Pichavant
- CIIL-Center for Infection and Immunity of Lille, Institut Pasteur de Lille, University of Lille, CNRS UMR9017, Inserm U1019, CHRU Lille, F-59000 Lille, France; (G.R.); (J.A.); (G.K.); (M.B.); (D.B.); (L.S.); (S.C.); (D.H.); (P.G.); (C.G.); (I.W.)
- Correspondence:
| |
Collapse
|
7
|
Bouvet M, Dubois-Deruy E, Turkieh A, Mulder P, Peugnet V, Chwastyniak M, Beseme O, Dechaumes A, Amouyel P, Richard V, Lamblin N, Pinet F. Desmin aggrephagy in rat and human ischemic heart failure through PKCζ and GSK3β as upstream signaling pathways. Cell Death Discov 2021; 7:153. [PMID: 34226534 PMCID: PMC8257599 DOI: 10.1038/s41420-021-00549-2] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2021] [Revised: 04/29/2021] [Accepted: 06/01/2021] [Indexed: 12/21/2022] Open
Abstract
Post-translational modifications of cardiac proteins could participate to left contractile dysfunction resulting in heart failure. Using a rat model of ischemic heart failure, we showed an accumulation of phosphorylated desmin leading to toxic aggregates in cardiomyocytes, but the cellular mechanisms are unknown. The same rat model was used to decipher the kinases involved in desmin phosphorylation and the proteolytic systems present in rat and human failing hearts. We used primary cultures of neonate rat cardiomyocytes for testing specific inhibitors of kinases and for characterizing the autophagic processes able to clear desmin aggregates. We found a significant increase of active PKCζ, no modulation of ubitiquitin-proteasome system, a defect in macroautophagy, and an activation of chaperone-mediated autophagy in heart failure rats. We validated in vitro that PKCζ inhibition induced a significant decrease of GSK3β and of soluble desmin. In vitro activation of ubiquitination of proteins and of chaperone-mediated autophagy is able to decrease soluble and insoluble forms of desmin in cardiomyocytes. These data demonstrate a novel signaling pathway implicating activation of PKCζ in desmin phosphorylation associated with a defect of proteolytic systems in ischemic heart failure, leading to desmin aggrephagy. Our in vitro data demonstrated that ubiquitination of proteins and chaperone-mediated autophagy are required for eliminating desmin aggregates with the contribution of its chaperone protein, α-crystallin Β-chain. Modulation of the kinases involved under pathological conditions may help preserving desmin intermediate filaments structure and thus protect the structural integrity of contractile apparatus of cardiomyocytes by limiting desmin aggregates formation.
Collapse
Affiliation(s)
- Marion Bouvet
- INSERM, Univ. Lille, CHU Lille, Institut Pasteur de Lille, U1167 - RID-AGE - Facteurs de risque et déterminants moléculaires des maladies liées au vieillissement, F-59000, Lille, France
| | - Emilie Dubois-Deruy
- INSERM, Univ. Lille, CHU Lille, Institut Pasteur de Lille, U1167 - RID-AGE - Facteurs de risque et déterminants moléculaires des maladies liées au vieillissement, F-59000, Lille, France
| | - Annie Turkieh
- INSERM, Univ. Lille, CHU Lille, Institut Pasteur de Lille, U1167 - RID-AGE - Facteurs de risque et déterminants moléculaires des maladies liées au vieillissement, F-59000, Lille, France
| | - Paul Mulder
- Normandie Univ, UNIROUEN, Inserm U1096, FHU-REMOD-VHF, 76000, Rouen, France
| | - Victoriane Peugnet
- INSERM, Univ. Lille, CHU Lille, Institut Pasteur de Lille, U1167 - RID-AGE - Facteurs de risque et déterminants moléculaires des maladies liées au vieillissement, F-59000, Lille, France
| | - Maggy Chwastyniak
- INSERM, Univ. Lille, CHU Lille, Institut Pasteur de Lille, U1167 - RID-AGE - Facteurs de risque et déterminants moléculaires des maladies liées au vieillissement, F-59000, Lille, France
| | - Olivia Beseme
- INSERM, Univ. Lille, CHU Lille, Institut Pasteur de Lille, U1167 - RID-AGE - Facteurs de risque et déterminants moléculaires des maladies liées au vieillissement, F-59000, Lille, France
| | - Arthur Dechaumes
- INSERM, Univ. Lille, CHU Lille, Institut Pasteur de Lille, U1167 - RID-AGE - Facteurs de risque et déterminants moléculaires des maladies liées au vieillissement, F-59000, Lille, France
| | - Philippe Amouyel
- INSERM, Univ. Lille, CHU Lille, Institut Pasteur de Lille, U1167 - RID-AGE - Facteurs de risque et déterminants moléculaires des maladies liées au vieillissement, F-59000, Lille, France
| | - Vincent Richard
- Normandie Univ, UNIROUEN, Inserm U1096, FHU-REMOD-VHF, 76000, Rouen, France
| | - Nicolas Lamblin
- INSERM, Univ. Lille, CHU Lille, Institut Pasteur de Lille, U1167 - RID-AGE - Facteurs de risque et déterminants moléculaires des maladies liées au vieillissement, F-59000, Lille, France
| | - Florence Pinet
- INSERM, Univ. Lille, CHU Lille, Institut Pasteur de Lille, U1167 - RID-AGE - Facteurs de risque et déterminants moléculaires des maladies liées au vieillissement, F-59000, Lille, France.
| |
Collapse
|
8
|
Dubois-Deruy E, Rémy G, Alard J, Kervoaze G, Chwastyniak M, Baron M, Beury D, Siegwald L, Caboche S, Hot D, Gosset P, Grangette C, Pinet F, Wolowczuk I, Pichavant M. Modelling the Impact of Chronic Cigarette Smoke Exposure in Obese Mice: Metabolic, Pulmonary, Intestinal, and Cardiac Issues. Nutrients 2020; 12:nu12030827. [PMID: 32244932 PMCID: PMC7175208 DOI: 10.3390/nu12030827] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2020] [Revised: 03/11/2020] [Accepted: 03/18/2020] [Indexed: 12/15/2022] Open
Abstract
Unhealthy lifestyle choices, such as bad eating behaviors and cigarette smoking, have major detrimental impacts on health. However, the inter-relations between obesity and smoking are still not fully understood. We thus developed an experimental model of high-fat diet-fed obese C57BL/6 male mice chronically exposed to cigarette smoke. Our study evaluated for the first time the resulting effects of the combined exposure to unhealthy diet and cigarette smoke on several metabolic, pulmonary, intestinal, and cardiac parameters. We showed that the chronic exposure to cigarette smoke modified the pattern of body fat distribution in favor of the visceral depots in obese mice, impaired the respiratory function, triggered pulmonary inflammation and emphysema, and was associated with gut microbiota dysbiosis, cardiac hypertrophy and myocardial fibrosis.
Collapse
Affiliation(s)
- Emilie Dubois-Deruy
- University of Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1167 - RID-AGE - Facteurs de risque et déterminants moléculaires des maladies liées au vieillissement, F-59000 Lille, France; (E.D.-D.); (M.C.); (F.P.)
| | - Gaëlle Rémy
- University of Lille, CNRS UMR9017, Inserm U1019, CHRU Lille, Institut Pasteur de Lille, CIIL - Center for Infection and Immunity of Lille, 59000 Lille, France; (G.R.); (J.A.); (G.K.); (M.B.); (D.B.); (L.S.); (S.C.); (D.H.); (P.G.); (C.G.); (I.W.)
| | - Jeanne Alard
- University of Lille, CNRS UMR9017, Inserm U1019, CHRU Lille, Institut Pasteur de Lille, CIIL - Center for Infection and Immunity of Lille, 59000 Lille, France; (G.R.); (J.A.); (G.K.); (M.B.); (D.B.); (L.S.); (S.C.); (D.H.); (P.G.); (C.G.); (I.W.)
| | - Gwenola Kervoaze
- University of Lille, CNRS UMR9017, Inserm U1019, CHRU Lille, Institut Pasteur de Lille, CIIL - Center for Infection and Immunity of Lille, 59000 Lille, France; (G.R.); (J.A.); (G.K.); (M.B.); (D.B.); (L.S.); (S.C.); (D.H.); (P.G.); (C.G.); (I.W.)
| | - Maggy Chwastyniak
- University of Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1167 - RID-AGE - Facteurs de risque et déterminants moléculaires des maladies liées au vieillissement, F-59000 Lille, France; (E.D.-D.); (M.C.); (F.P.)
| | - Morgane Baron
- University of Lille, CNRS UMR9017, Inserm U1019, CHRU Lille, Institut Pasteur de Lille, CIIL - Center for Infection and Immunity of Lille, 59000 Lille, France; (G.R.); (J.A.); (G.K.); (M.B.); (D.B.); (L.S.); (S.C.); (D.H.); (P.G.); (C.G.); (I.W.)
| | - Delphine Beury
- University of Lille, CNRS UMR9017, Inserm U1019, CHRU Lille, Institut Pasteur de Lille, CIIL - Center for Infection and Immunity of Lille, 59000 Lille, France; (G.R.); (J.A.); (G.K.); (M.B.); (D.B.); (L.S.); (S.C.); (D.H.); (P.G.); (C.G.); (I.W.)
| | - Léa Siegwald
- University of Lille, CNRS UMR9017, Inserm U1019, CHRU Lille, Institut Pasteur de Lille, CIIL - Center for Infection and Immunity of Lille, 59000 Lille, France; (G.R.); (J.A.); (G.K.); (M.B.); (D.B.); (L.S.); (S.C.); (D.H.); (P.G.); (C.G.); (I.W.)
| | - Ségolène Caboche
- University of Lille, CNRS UMR9017, Inserm U1019, CHRU Lille, Institut Pasteur de Lille, CIIL - Center for Infection and Immunity of Lille, 59000 Lille, France; (G.R.); (J.A.); (G.K.); (M.B.); (D.B.); (L.S.); (S.C.); (D.H.); (P.G.); (C.G.); (I.W.)
| | - David Hot
- University of Lille, CNRS UMR9017, Inserm U1019, CHRU Lille, Institut Pasteur de Lille, CIIL - Center for Infection and Immunity of Lille, 59000 Lille, France; (G.R.); (J.A.); (G.K.); (M.B.); (D.B.); (L.S.); (S.C.); (D.H.); (P.G.); (C.G.); (I.W.)
| | - Philippe Gosset
- University of Lille, CNRS UMR9017, Inserm U1019, CHRU Lille, Institut Pasteur de Lille, CIIL - Center for Infection and Immunity of Lille, 59000 Lille, France; (G.R.); (J.A.); (G.K.); (M.B.); (D.B.); (L.S.); (S.C.); (D.H.); (P.G.); (C.G.); (I.W.)
| | - Corinne Grangette
- University of Lille, CNRS UMR9017, Inserm U1019, CHRU Lille, Institut Pasteur de Lille, CIIL - Center for Infection and Immunity of Lille, 59000 Lille, France; (G.R.); (J.A.); (G.K.); (M.B.); (D.B.); (L.S.); (S.C.); (D.H.); (P.G.); (C.G.); (I.W.)
| | - Florence Pinet
- University of Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1167 - RID-AGE - Facteurs de risque et déterminants moléculaires des maladies liées au vieillissement, F-59000 Lille, France; (E.D.-D.); (M.C.); (F.P.)
| | - Isabelle Wolowczuk
- University of Lille, CNRS UMR9017, Inserm U1019, CHRU Lille, Institut Pasteur de Lille, CIIL - Center for Infection and Immunity of Lille, 59000 Lille, France; (G.R.); (J.A.); (G.K.); (M.B.); (D.B.); (L.S.); (S.C.); (D.H.); (P.G.); (C.G.); (I.W.)
| | - Muriel Pichavant
- University of Lille, CNRS UMR9017, Inserm U1019, CHRU Lille, Institut Pasteur de Lille, CIIL - Center for Infection and Immunity of Lille, 59000 Lille, France; (G.R.); (J.A.); (G.K.); (M.B.); (D.B.); (L.S.); (S.C.); (D.H.); (P.G.); (C.G.); (I.W.)
- Correspondence: ; Tel.: +33-320-877-965
| |
Collapse
|
9
|
Dubois-Deruy E, Gelinas R, Beauloye C, Esfahani H, Michel LYM, Dessy C, Bertrand L, Balligand JL. Beta 3 adrenoreceptors protect from hypertrophic remodelling through AMP-activated protein kinase and autophagy. ESC Heart Fail 2020; 7:920-932. [PMID: 32154661 PMCID: PMC7261558 DOI: 10.1002/ehf2.12648] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2019] [Revised: 01/07/2020] [Accepted: 02/04/2020] [Indexed: 12/31/2022] Open
Abstract
Aims The abundance of beta 3‐adrenergic receptors (β3‐ARs) is upregulated in diseased human myocardium. We previously showed that cardiac‐specific expression of β3‐AR inhibits the hypertrophic response to neurohormonal stimulation. Here, we further analysed signalling pathways involved in the anti‐hypertrophic effect of β3‐AR. Methods and results In vitro hypertrophic responses to phenylephrine (PE) were analysed in neonatal rat ventricular myocytes (NRVM) infected with a recombinant adenovirus expressing the human β3‐AR (AdVhβ3). We confirmed results in mice with cardiomyocyte‐specific moderate expression of human β3‐AR (β3‐TG) and wild‐type (WT) littermates submitted to thoracic transverse aortic constriction (TAC) for 9 weeks. We observed a colocalization of β3‐AR with the AMP‐activated protein kinase (AMPK) both in neonatal rat and in adult mouse cardiomyocytes. Treatment of NRVM with PE induced hypertrophy and a decrease in phosphorylation of Thr172‐AMPK (/2, P = 0.0487) and phosphorylation of Ser79‐acetyl‐CoA carboxylase (ACC) (/2.6, P = 0.0317), inducing an increase in phosphorylated Ser235/236 S6 protein (×2.5, P = 0.0367) known to be involved in protein synthesis. These effects were reproduced by TAC in WT mice but restored to basal levels in β3‐AR expressing cells/mice. siRNA targeting of AMPK partly abrogated the anti‐hypertrophic effect of β3‐AR in response to PE in NRVM. Concomitant with hypertrophy, autophagy was decreased by PE, as measured by microtubule‐associated protein 1 light chain 3 (LC3)‐II/LC3‐I ratio (/2.6, P = 0.0010) and p62 abundance (×3, P = 0.0016) in NRVM or by TAC in WT mice (LC3‐II/LC3‐I ratio: /5.4, P = 0.0159), but preserved in human β3‐AR expressing cells and mice, together with reduced hypertrophy. Conclusions Cardiac‐specific moderate expression of β3‐AR inhibits the hypertrophic response in part through AMPK activation followed by inhibition of protein synthesis and preservation of autophagy. Activation of the cardiac β3‐AR pathway may provide future therapeutic avenues for the modulation of hypertrophic remodelling.
Collapse
Affiliation(s)
- Emilie Dubois-Deruy
- Institut de Recherche Expérimentale et Clinique (IREC), Pole of Pharmacology and Therapeutics (FATH), Université Catholique de Louvain (UCLouvain) and Cliniques Universitaires Saint-Luc, B1.57.04, 57 Avenue Hippocrate, Brussels, 1200, Belgium
| | - Roselle Gelinas
- Institut de Recherche Expérimentale et Clinique (IREC), Pole of Cardiovascular Pathology (CARD), Université Catholique de Louvain (UCLouvain) and Cliniques Universitaires Saint-Luc, Brussels, Belgium
| | - Christophe Beauloye
- Institut de Recherche Expérimentale et Clinique (IREC), Pole of Cardiovascular Pathology (CARD), Université Catholique de Louvain (UCLouvain) and Cliniques Universitaires Saint-Luc, Brussels, Belgium.,Division of Cardiology, Cliniques Universitaires Saint-Luc, Brussels, Belgium
| | - Hrag Esfahani
- Institut de Recherche Expérimentale et Clinique (IREC), Pole of Pharmacology and Therapeutics (FATH), Université Catholique de Louvain (UCLouvain) and Cliniques Universitaires Saint-Luc, B1.57.04, 57 Avenue Hippocrate, Brussels, 1200, Belgium
| | - Lauriane Y M Michel
- Institut de Recherche Expérimentale et Clinique (IREC), Pole of Pharmacology and Therapeutics (FATH), Université Catholique de Louvain (UCLouvain) and Cliniques Universitaires Saint-Luc, B1.57.04, 57 Avenue Hippocrate, Brussels, 1200, Belgium
| | - Chantal Dessy
- Institut de Recherche Expérimentale et Clinique (IREC), Pole of Pharmacology and Therapeutics (FATH), Université Catholique de Louvain (UCLouvain) and Cliniques Universitaires Saint-Luc, B1.57.04, 57 Avenue Hippocrate, Brussels, 1200, Belgium
| | - Luc Bertrand
- Institut de Recherche Expérimentale et Clinique (IREC), Pole of Cardiovascular Pathology (CARD), Université Catholique de Louvain (UCLouvain) and Cliniques Universitaires Saint-Luc, Brussels, Belgium
| | - Jean-Luc Balligand
- Institut de Recherche Expérimentale et Clinique (IREC), Pole of Pharmacology and Therapeutics (FATH), Université Catholique de Louvain (UCLouvain) and Cliniques Universitaires Saint-Luc, B1.57.04, 57 Avenue Hippocrate, Brussels, 1200, Belgium
| |
Collapse
|
10
|
Michel L, Dubois-Deruy E, Gelinas R, Esfahani H, Roelants V, Bertrand L, Beauloye C, Balligand J. Cardiac myocyte-specific expression of beta3-adrenergic receptors sustains AMPK activation and glucose uptake while reducing hypertrophy following pressure overload. Archives of Cardiovascular Diseases Supplements 2019. [DOI: 10.1016/j.acvdsp.2019.02.134] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
11
|
Gélinas R, Mailleux F, Dontaine J, Bultot L, Demeulder B, Ginion A, Daskalopoulos EP, Esfahani H, Dubois-Deruy E, Lauzier B, Gauthier C, Olson AK, Bouchard B, Des Rosiers C, Viollet B, Sakamoto K, Balligand JL, Vanoverschelde JL, Beauloye C, Horman S, Bertrand L. AMPK activation counteracts cardiac hypertrophy by reducing O-GlcNAcylation. Nat Commun 2018; 9:374. [PMID: 29371602 PMCID: PMC5785516 DOI: 10.1038/s41467-017-02795-4] [Citation(s) in RCA: 165] [Impact Index Per Article: 27.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2017] [Accepted: 12/28/2017] [Indexed: 12/11/2022] Open
Abstract
AMP-activated protein kinase (AMPK) has been shown to inhibit cardiac hypertrophy. Here, we show that submaximal AMPK activation blocks cardiomyocyte hypertrophy without affecting downstream targets previously suggested to be involved, such as p70 ribosomal S6 protein kinase, calcineurin/nuclear factor of activated T cells (NFAT) and extracellular signal-regulated kinases. Instead, cardiomyocyte hypertrophy is accompanied by increased protein O-GlcNAcylation, which is reversed by AMPK activation. Decreasing O-GlcNAcylation by inhibitors of the glutamine:fructose-6-phosphate aminotransferase (GFAT), blocks cardiomyocyte hypertrophy, mimicking AMPK activation. Conversely, O-GlcNAcylation-inducing agents counteract the anti-hypertrophic effect of AMPK. In vivo, AMPK activation prevents myocardial hypertrophy and the concomitant rise of O-GlcNAcylation in wild-type but not in AMPKα2-deficient mice. Treatment of wild-type mice with O-GlcNAcylation-inducing agents reverses AMPK action. Finally, we demonstrate that AMPK inhibits O-GlcNAcylation by mainly controlling GFAT phosphorylation, thereby reducing O-GlcNAcylation of proteins such as troponin T. We conclude that AMPK activation prevents cardiac hypertrophy predominantly by inhibiting O-GlcNAcylation.
Collapse
Affiliation(s)
- Roselle Gélinas
- Pole of Cardiovascular Research, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, 1200, Belgium
| | - Florence Mailleux
- Pole of Cardiovascular Research, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, 1200, Belgium
| | - Justine Dontaine
- Pole of Cardiovascular Research, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, 1200, Belgium
| | - Laurent Bultot
- Pole of Cardiovascular Research, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, 1200, Belgium
| | - Bénédicte Demeulder
- Pole of Cardiovascular Research, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, 1200, Belgium
| | - Audrey Ginion
- Pole of Cardiovascular Research, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, 1200, Belgium
| | - Evangelos P Daskalopoulos
- Pole of Cardiovascular Research, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, 1200, Belgium
| | - Hrag Esfahani
- Pole of Pharmacotherapy, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, 1200, Belgium
| | - Emilie Dubois-Deruy
- Pole of Pharmacotherapy, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, 1200, Belgium
| | - Benjamin Lauzier
- l'institut du thorax, INSERM, CNRS, Univ. Nantes, Nantes, 44007, France
| | - Chantal Gauthier
- l'institut du thorax, INSERM, CNRS, Univ. Nantes, Nantes, 44007, France
| | - Aaron K Olson
- Department of Pediatrics, University of Washington School of Medicine and Seattle Children's Research Institute, Seattle, 98105-0371, WA, USA.,Montreal Heart Institute, Montreal, H1T 1C8, Canada
| | | | - Christine Des Rosiers
- Montreal Heart Institute, Montreal, H1T 1C8, Canada.,Department of Nutrition, Université de Montréal, Montreal, H3T 1A8, Canada
| | - Benoit Viollet
- Institut Cochin, INSERM U1016, 75014, Paris, France.,CNRS UMR8104, 75014, Paris, France.,Université Paris Descartes, Sorbonne Paris Cité, Paris, 75014, France
| | - Kei Sakamoto
- Nestlé Institute of Health Sciences SA, Lausanne, 1015, Switzerland
| | - Jean-Luc Balligand
- Pole of Pharmacotherapy, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, 1200, Belgium
| | - Jean-Louis Vanoverschelde
- Pole of Cardiovascular Research, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, 1200, Belgium.,Division of Cardiology, Cliniques Universitaires Saint-Luc, Brussels, 1200, Belgium
| | - Christophe Beauloye
- Pole of Cardiovascular Research, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, 1200, Belgium.,Division of Cardiology, Cliniques Universitaires Saint-Luc, Brussels, 1200, Belgium
| | - Sandrine Horman
- Pole of Cardiovascular Research, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, 1200, Belgium
| | - Luc Bertrand
- Pole of Cardiovascular Research, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, 1200, Belgium.
| |
Collapse
|
12
|
Mercier T, Bouvet M, Dubois-Deruy E, Dechaumes A, Beseme O, Richard V, Mulder P, Pinet F. Interplay Between Phosphorylation and O-GlcNAcylation of Sarcomeric Proteins in Ischemic Heart Failure. Front Endocrinol (Lausanne) 2018; 9:598. [PMID: 30344511 PMCID: PMC6182077 DOI: 10.3389/fendo.2018.00598] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/21/2018] [Accepted: 09/19/2018] [Indexed: 11/13/2022] Open
Abstract
Post-translational modifications (PTMs) of sarcomeric proteins could participate to left ventricular (LV) remodeling and contractile dysfunction leading in advanced heart failure (HF) with altered ejection fraction. Using an experimental rat model of HF (ligation of left coronary artery) and phosphoproteomic analysis, we identified an increase of desmin phosphorylation and a decrease of desmin O-N-acetylglucosaminylation (O-GlcNAcylation). We aim to characterize interplay between phosphorylation and O-GlcNAcylation for desmin in primary cultures of cardiomyocyte by specific O-GlcNAcase (OGA) inhibition with thiamet G and silencing O-GlcNAc transferase (OGT) and, in perfused heart perfused with thiamet G in sham- and HF-rats. In each model, we found an efficiency of O-GlcNAcylation modulation characterized by the levels of O-GlcNAcylated proteins and OGT expression (for silencing experiments in cells). In perfused heart, we found an improvement of cardiac function under OGA inhibition. But none of the treatments either in in vitro or ex vivo cardiac models, induced a modulation of desmin, phosphorylated and O-GlcNAcylated desmin expression, despite the presence of O-GlcNAc moities in cardiac desmin. Our data suggests no interplay between phosphorylation and O-GlcNAcylation of desmin in HF post-myocardial infarction. The future requires finding the targets in heart involved in cardiac improvement under thiamet G treatment.
Collapse
Affiliation(s)
- Thomas Mercier
- INSERM U1167 Unité d'Epidémiologie et de Santé Publique, Lille, France
| | - Marion Bouvet
- INSERM U1167 Unité d'Epidémiologie et de Santé Publique, Lille, France
| | | | - Arthur Dechaumes
- INSERM U1167 Unité d'Epidémiologie et de Santé Publique, Lille, France
| | - Olivia Beseme
- INSERM U1167 Unité d'Epidémiologie et de Santé Publique, Lille, France
| | - Vincent Richard
- INSERM UMR1096, Endothélium, Valvulopathies et Insuffisance Cardiaque, Rouen, France
| | - Paul Mulder
- INSERM UMR1096, Endothélium, Valvulopathies et Insuffisance Cardiaque, Rouen, France
| | - Florence Pinet
- INSERM U1167 Unité d'Epidémiologie et de Santé Publique, Lille, France
- *Correspondence: Florence Pinet
| |
Collapse
|
13
|
Hermida N, Michel L, Esfahani H, Dubois-Deruy E, Hammond J, Bouzin C, Markl A, Colin H, Steenbergen AV, De Meester C, Beauloye C, Horman S, Yin X, Mayr M, Balligand JL. Cardiac myocyte β3-adrenergic receptors prevent myocardial fibrosis by modulating oxidant stress-dependent paracrine signaling. Eur Heart J 2017; 39:888-898. [DOI: 10.1093/eurheartj/ehx366] [Citation(s) in RCA: 43] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/02/2016] [Accepted: 06/08/2017] [Indexed: 01/08/2023] Open
Affiliation(s)
- Nerea Hermida
- Department of Medicine, Pole of Pharmacology and Therapeutics (FATH), Institut de Recherche Expérimentale et Clinique (IREC), Cliniques Universitaires Saint-Luc, Université catholique de Louvain, 52 avenue Mounier, 1200 Brussels, Belgium
| | - Lauriane Michel
- Department of Medicine, Pole of Pharmacology and Therapeutics (FATH), Institut de Recherche Expérimentale et Clinique (IREC), Cliniques Universitaires Saint-Luc, Université catholique de Louvain, 52 avenue Mounier, 1200 Brussels, Belgium
| | - Hrag Esfahani
- Department of Medicine, Pole of Pharmacology and Therapeutics (FATH), Institut de Recherche Expérimentale et Clinique (IREC), Cliniques Universitaires Saint-Luc, Université catholique de Louvain, 52 avenue Mounier, 1200 Brussels, Belgium
| | - Emilie Dubois-Deruy
- Department of Medicine, Pole of Pharmacology and Therapeutics (FATH), Institut de Recherche Expérimentale et Clinique (IREC), Cliniques Universitaires Saint-Luc, Université catholique de Louvain, 52 avenue Mounier, 1200 Brussels, Belgium
| | - Joanna Hammond
- Department of Medicine, Pole of Pharmacology and Therapeutics (FATH), Institut de Recherche Expérimentale et Clinique (IREC), Cliniques Universitaires Saint-Luc, Université catholique de Louvain, 52 avenue Mounier, 1200 Brussels, Belgium
| | - Caroline Bouzin
- Department of Medicine, Pole of Pharmacology and Therapeutics (FATH), Institut de Recherche Expérimentale et Clinique (IREC), Cliniques Universitaires Saint-Luc, Université catholique de Louvain, 52 avenue Mounier, 1200 Brussels, Belgium
| | - Andreas Markl
- Department of Medicine, Pole of Pharmacology and Therapeutics (FATH), Institut de Recherche Expérimentale et Clinique (IREC), Cliniques Universitaires Saint-Luc, Université catholique de Louvain, 52 avenue Mounier, 1200 Brussels, Belgium
| | - Henri Colin
- Department of Medicine, Pole of Pharmacology and Therapeutics (FATH), Institut de Recherche Expérimentale et Clinique (IREC), Cliniques Universitaires Saint-Luc, Université catholique de Louvain, 52 avenue Mounier, 1200 Brussels, Belgium
| | - Anne Van Steenbergen
- Division of Cardiology, Pole of Cardiovascular Research, Institut de Recherche Expérimentale et Clinique (IREC), Cliniques Universitaires Saint-Luc, Université catholique de Louvain, 10 Avenue Hippocrate, 1200 Brussels, Belgium
| | - Christophe De Meester
- Division of Cardiology, Pole of Cardiovascular Research, Institut de Recherche Expérimentale et Clinique (IREC), Cliniques Universitaires Saint-Luc, Université catholique de Louvain, 10 Avenue Hippocrate, 1200 Brussels, Belgium
| | - Christophe Beauloye
- Division of Cardiology, Pole of Cardiovascular Research, Institut de Recherche Expérimentale et Clinique (IREC), Cliniques Universitaires Saint-Luc, Université catholique de Louvain, 10 Avenue Hippocrate, 1200 Brussels, Belgium
| | - Sandrine Horman
- Division of Cardiology, Pole of Cardiovascular Research, Institut de Recherche Expérimentale et Clinique (IREC), Cliniques Universitaires Saint-Luc, Université catholique de Louvain, 10 Avenue Hippocrate, 1200 Brussels, Belgium
| | - Xiaoke Yin
- King’s British Heart Foundation Center, King’s College, 125 Coldharbour Lane, SE5 9NU, London, UK
| | - Manuel Mayr
- King’s British Heart Foundation Center, King’s College, 125 Coldharbour Lane, SE5 9NU, London, UK
| | - Jean-Luc Balligand
- Department of Medicine, Pole of Pharmacology and Therapeutics (FATH), Institut de Recherche Expérimentale et Clinique (IREC), Cliniques Universitaires Saint-Luc, Université catholique de Louvain, 52 avenue Mounier, 1200 Brussels, Belgium
| |
Collapse
|
14
|
Bouvet M, Dubois-Deruy E, Alayi TD, Mulder P, El Amranii M, Beseme O, Amouyel P, Richard V, Tomavo S, Pinet F. Increased level of phosphorylated desmin and its degradation products in heart failure. Biochem Biophys Rep 2016; 6:54-62. [PMID: 28955862 PMCID: PMC5600436 DOI: 10.1016/j.bbrep.2016.02.014] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2015] [Revised: 02/11/2016] [Accepted: 02/25/2016] [Indexed: 01/03/2023] Open
Abstract
Although several risk factors such as infarct size have been identified, the progression/severity of heart failure (HF) remains difficult to predict in clinical practice. Using an experimental rat model of ischemic HF and phosphoproteomic technology, we found an increased level of phosphorylated desmin in the left ventricle (LV) of HF-rats. The purpose of the present work is to assess whether desmin is a circulating or only a tissue biomarker of HF. We used several antibodies in order to detect desmin, its proteolytic fragments and its phosphorylated form in LV and plasma by western blot, phosphate affinity electrophoresis, mass spectrometry and immunofluorescence. Plasma was treated with combinatorial peptide ligand library or depleted for albumin and immunoglobulins to increase the sensitivity of detection. We found a 2-fold increased serine-desmin phosphorylation in the LV of HF-rats, mainly in the insoluble fraction, suggesting the formation of desmin aggregates. Desmin cleavage products were also detected in the LV of HF rats, indicating that the increased phosphorylation of desmin results in more susceptibility to proteolytic activity, likely mediated by calpain activity. The native desmin and its degradation products were undetectable in the plasma of rat, mouse or human. These data suggest the potential of serine-phosphorylated form of desmin and its degradation products, but not of desmin itself, as tissue but not circulating biomarkers of HF. Desmin is mainly expressed in insoluble fraction of rat left ventricle. In experimental heart failure, desmin is highly phosphorylated in serine. Desmin and its degradation products are not detected in plasma.
Collapse
Affiliation(s)
- Marion Bouvet
- INSERM, U1167, University Lille, Institut Pasteur de Lille, F-59000 Lille, France
| | - Emilie Dubois-Deruy
- INSERM, U1167, University Lille, Institut Pasteur de Lille, F-59000 Lille, France
| | - Tchilabalo Dilezitoko Alayi
- University Lille, CNRS UMR8204, INSERM, U1019, Institut Pasteur de Lille, Plateforme de Protéomique et des Peptides Modifiés (P3M), F-59000 Lille, France
| | - Paul Mulder
- INSERM, U1096, University of Rouen, Institute for Research and Innovation in Biomedicine, F-76000 Rouen, France
| | - Myriam El Amranii
- University Lille, CNRS UMR8204, INSERM, U1019, Institut Pasteur de Lille, Plateforme de Protéomique et des Peptides Modifiés (P3M), F-59000 Lille, France
| | - Olivia Beseme
- INSERM, U1167, University Lille, Institut Pasteur de Lille, F-59000 Lille, France
| | - Philippe Amouyel
- INSERM, U1167, University Lille, Institut Pasteur de Lille, Centre Hospitalier Régional et Universitaire de Lille, F-59000 Lille, France
| | - Vincent Richard
- INSERM, U1096, University of Rouen, Institute for Research and Innovation in Biomedicine, F-76000 Rouen, France
| | - Stanislas Tomavo
- University Lille, CNRS UMR8204, INSERM, U1019, Institut Pasteur de Lille, Plateforme de Protéomique et des Peptides Modifiés (P3M), F-59000 Lille, France
| | - Florence Pinet
- INSERM, U1167, University Lille, Institut Pasteur de Lille, F-59000 Lille, France
| |
Collapse
|
15
|
Dubois-Deruy E, Belliard A, Mulder P, Bouvet M, Smet-Nocca C, Janel S, Lafont F, Beseme O, Amouyel P, Richard V, Pinet F. Interplay between troponin T phosphorylation and O-N-acetylglucosaminylation in ischaemic heart failure. Cardiovasc Res 2015; 107:56-65. [PMID: 25916824 DOI: 10.1093/cvr/cvv136] [Citation(s) in RCA: 35] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/24/2014] [Accepted: 04/15/2015] [Indexed: 11/13/2022] Open
Abstract
AIMS Previous studies have reported that decreased serine 208 phosphorylation of troponin T (TnTpSer208) is associated with ischaemic heart failure (HF), but the molecular mechanisms and functional consequences of these changes are unknown. The aim of this study was to characterize the balance between serine phosphorylation and O-N-acetylglucosaminylation (O-GlcNAcylation) of TnT in HF, its mechanisms, and the consequences of modulating these post-translational modifications. METHODS AND RESULTS Decreased TnTpSer208 levels in the left ventricles of HF male Wistar rats were associated with reduced expression of PKCε but not of other cardiac PKC isoforms. In both isolated perfused rat hearts and cultured neonatal cardiomyocytes, the PKCε inhibitor εV1-2 decreased TnTpSer208 and simultaneously decreased cardiac contraction in isolated hearts and beating amplitude in neonatal cardiomyocytes (measured by atomic force microscopy). Down-regulating PKCε by silencing RNA (siRNA) also reduced TnTpSer208 in these cardiomyocytes, and PKCε-/- mice had lower TnTpSer208 levels than the wild-type. In parallel, HF increased TnT O-GlcNAcylation via both increased O-GlcNAc transferase and decreased O-GlcNAcase activity. Increasing O-GlcNAcylation (via O-GlcNAcase inhibition with Thiamet G) decreased TnTpSer208 in isolated hearts, while reducing O-GlcNAcylation (O-GlcNAc transferase siRNA) increased TnTpSer208 in neonatal cardiomyocytes. Mass spectrometry and NMR analysis identified O-GlcNAcylation of TnT on Ser190. CONCLUSION These data demonstrate interplay between Ser208 phosphorylation and Ser190 O-GlcNAcylation of TnT in ischaemic HF, linked to decreased activity of both PKCε and O-GlcNAcase and increased O-GlcNAc transferase activity. Modulation of these post-translational modifications of TnT may be a new therapeutic strategy in HF.
Collapse
Affiliation(s)
- Emilie Dubois-Deruy
- INSERM, U1167, 1 rue du Professeur Calmette, Lille, France Institut Pasteur de Lille, Lille, France University of Lille Nord de France, Lille, France
| | - Aude Belliard
- INSERM, U1167, 1 rue du Professeur Calmette, Lille, France Institut Pasteur de Lille, Lille, France University of Lille Nord de France, Lille, France
| | - Paul Mulder
- Inserm U1096, Rouen, France Institute for Research and Innovation in Biomedicine, University of Rouen, Rouen, France
| | - Marion Bouvet
- INSERM, U1167, 1 rue du Professeur Calmette, Lille, France Institut Pasteur de Lille, Lille, France University of Lille Nord de France, Lille, France
| | - Caroline Smet-Nocca
- University of Lille Nord de France, Lille, France CNRS UMR 8576, Villeneuve D'Ascq, France
| | | | - Frank Lafont
- Institut Pasteur de Lille, Lille, France University of Lille Nord de France, Lille, France Bioimaging Center Lille Nord de France, Lille, France CNRS UMR 8204, INSERM U1019, Lille, France
| | - Olivia Beseme
- INSERM, U1167, 1 rue du Professeur Calmette, Lille, France Institut Pasteur de Lille, Lille, France University of Lille Nord de France, Lille, France
| | - Philippe Amouyel
- INSERM, U1167, 1 rue du Professeur Calmette, Lille, France Institut Pasteur de Lille, Lille, France University of Lille Nord de France, Lille, France Centre Hospitalier Régional et Universitaire de Lille, Lille, France
| | - Vincent Richard
- Inserm U1096, Rouen, France Institute for Research and Innovation in Biomedicine, University of Rouen, Rouen, France
| | - Florence Pinet
- INSERM, U1167, 1 rue du Professeur Calmette, Lille, France Institut Pasteur de Lille, Lille, France University of Lille Nord de France, Lille, France
| |
Collapse
|
16
|
Hermida N, Dubois-Deruy E, Hammond J, Hamelet J, Markl A, Mayr M, Balligand JL. 309Protection from cardiac fibrosis is induced by beta3 adrenergic receptor in cardiac myocyte through inhibition of paracrine signalling to fibroblast : proteomic analysis of the myocyte secretome. Cardiovasc Res 2014. [DOI: 10.1093/cvr/cvu090.2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
17
|
Dubois-Deruy E, Gelinas R, Hammond J, Gotz K, Nikolaev V, Manoury B, Esfahani H, Dessy C, Bertrand L, Balligand JL. 290β-3 adrenoreceptors protect from hypertrophic remodelling through nitric oxide synthase & AMP-activated protein kinase dependent signaling pathways. Cardiovasc Res 2014. [DOI: 10.1093/cvr/cvu087.4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
18
|
Belge C, Hammond J, Dubois-Deruy E, Manoury B, Hamelet J, Beauloye C, Markl A, Pouleur AC, Bertrand L, Esfahani H, Jnaoui K, Götz KR, Nikolaev VO, Vanderper A, Herijgers P, Lobysheva I, Iaccarino G, Hilfiker-Kleiner D, Tavernier G, Langin D, Dessy C, Balligand JL. Enhanced expression of β3-adrenoceptors in cardiac myocytes attenuates neurohormone-induced hypertrophic remodeling through nitric oxide synthase. Circulation 2013; 129:451-62. [PMID: 24190960 DOI: 10.1161/circulationaha.113.004940] [Citation(s) in RCA: 103] [Impact Index Per Article: 9.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/16/2023]
Abstract
BACKGROUND β1-2-adrenergic receptors (AR) are key regulators of cardiac contractility and remodeling in response to catecholamines. β3-AR expression is enhanced in diseased human myocardium, but its impact on remodeling is unknown. METHODS AND RESULTS Mice with cardiac myocyte-specific expression of human β3-AR (β3-TG) and wild-type (WT) littermates were used to compare myocardial remodeling in response to isoproterenol (Iso) or Angiotensin II (Ang II). β3-TG and WT had similar morphometric and hemodynamic parameters at baseline. β3-AR colocalized with caveolin-3, endothelial nitric oxide synthase (NOS) and neuronal NOS in adult transgenic myocytes, which constitutively produced more cyclic GMP, detected with a new transgenic FRET sensor. Iso and Ang II produced hypertrophy and fibrosis in WT mice, but not in β3-TG mice, which also had less re-expression of fetal genes and transforming growth factor β1. Protection from Iso-induced hypertrophy was reversed by nonspecific NOS inhibition at low dose Iso, and by preferential neuronal NOS inhibition at high-dose Iso. Adenoviral overexpression of β3-AR in isolated cardiac myocytes also increased NO production and attenuated hypertrophy to Iso and phenylephrine. Hypertrophy was restored on NOS or protein kinase G inhibition. Mechanistically, β3-AR overexpression inhibited phenylephrine-induced nuclear factor of activated T-cell activation. CONCLUSIONS Cardiac-specific overexpression of β3-AR does not affect cardiac morphology at baseline but inhibits the hypertrophic response to neurohormonal stimulation in vivo and in vitro, through a NOS-mediated mechanism. Activation of the cardiac β3-AR pathway may provide future therapeutic avenues for the modulation of hypertrophic remodeling.
Collapse
Affiliation(s)
- Catharina Belge
- Institut de Recherche Expérimentale et Clinique (IREC), Pole of Pharmacology and Therapeutics (FATH), Université Catholique de Louvain, Brussels, Belgium (C.B., J. Hammond, E.D.-D., B.M., J. Hamelet, A.M., H.E., K.J., I.L., C.D., J.-L.B.); Pole of Cardiovascular Pathology and Cliniques Universitaires Saint-Luc, Université catholique de Louvain, Brussels, Belgium (C.B., A.-C.P., L.B.); the Division of Cardiology and Pneumology, University of Goettingen, Goettingen, Germany (K.R.G., V.O.N.); the Department of Cardiovascular Sciences, Katholieke Universiteit Leuven, Belgium (A.V., P.H.); the Department of Medicine and Surgery, University of Salerno and RCCS "Multimedica," Milano, Italy (G.I.); Molecular Cardiology, Medizinische Hochschule Hannover, Germany (D.H.-K.); and Université Paul Sabatier, Inserm UMR 1048 - I2MC, Hôpitaux de Toulouse, France (G.T., D.L.)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Dubois-Deruy E, Hammond J, Gelinas R, Manoury B, Hamelet J, Lobysheva I, Langin D, Dessy C, Bertrand L, Balligand JL. AMP-activated protein kinase dependent signaling pathways and modulation of autophagy are involved in the anti-hypertrophic effect of the human beta 3 adrenoreceptor. Eur Heart J 2013. [DOI: 10.1093/eurheartj/eht307.38] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
20
|
Dubois-Deruy E, Belliard A, Mulder P, Chwastyniak M, Beseme O, Henry JP, Thuillez C, Amouyel P, Richard V, Pinet F. Circulating plasma serine208-phosphorylated troponin T levels are indicator of cardiac dysfunction. J Cell Mol Med 2013; 17:1335-44. [PMID: 23905701 PMCID: PMC4159027 DOI: 10.1111/jcmm.12112] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/12/2013] [Accepted: 07/10/2013] [Indexed: 01/08/2023] Open
Abstract
Heart failure (HF) following myocardial infarction (MI) is characterized by progressive alterations of left ventricular (LV) structure and function, named LV remodelling. Although several risk factors such as infarct size have been identified, HF remains difficult to predict in clinical practice. Recently, using phosphoproteomic technology, we found that serine(208)-phosphorylated troponin T (P-Ser(208)-TnT) decreases in LV of HF rats. Our aim was to determine the performance of P-Ser(208)-TnT as plasma biomarker of HF compared to conventional cardiac biomarkers such as B-type natriuretic peptide (BNP), cardiac troponin I (cTnI), C-reactive protein (CRP) or tissue inhibitor of metalloproteinase I (TIMP-1) measured by x-MAP technology, as well as its capacity to reflect a pharmacological improvement of HF. We observed a significant increase of BNP, TnT and cTnI levels and a significant decrease of P-Ser(208)-TnT and TIMP-1 in the plasma of 2-month-MI rats compared with control rats with no modulation of CRP level. Circulating levels of P-Ser(208)-TnT were shown to be associated with most of the echocardiographic and haemodynamic parameters of cardiac function. We verified that the decrease of P-Ser(208)-TnT was not because of an excess of phosphatase activity in plasma of HF rats. Two-month-MI rats treated with the heart rate reducing agent ivabradine had improved LV function and increased plasma levels of P-Ser(208)-TnT. Thus, circulating phosphorylated troponin T is a highly sensitive biological indicator of cardiac dysfunction and has the potentiality of a new biomarker of HF post-MI, and of a surrogate marker for the efficacy of a successful treatment of HF.
Collapse
Affiliation(s)
- Emilie Dubois-Deruy
- INSERM, U744, Lille, France; Institut Pasteur de Lille, Lille, France; University of Lille 2, IFR141, Lille, France
| | | | | | | | | | | | | | | | | | | |
Collapse
|